
|Articles|March 23, 2015
- Immunotherapy (Issue 5)
- Volume 5
- Issue 1
Immunotherapy in GU Cancers
Author(s)Mark A. Rubin, MD
Mark A. Rubin, MD, director, Institute for Precision Medicine, Weill Cornell Medical College, discusses immunotherapy in the field of genitourinary cancers.
Advertisement
Mark A. Rubin, MD, director, Institute for Precision Medicine, Weill Cornell Medical College, discusses immunotherapy in the field of genitourinary cancers.
<<<
Articles in this issue
over 10 years ago
The Rationale for Immunotherapy in NSCLCover 10 years ago
Maximizing Immunotherapy Approaches in Hard-to-Treat Cancersover 10 years ago
Rich Immunotherapy Pipeline for Melanoma Under Wayover 10 years ago
Tumor Antigens and Their Role in Immune Response in Melanomaover 10 years ago
Major Programs Under Way in Immuno-Oncologyover 10 years ago
PD-1 Inhibitors for MelanomaAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5






































